Business News • PR NewsWire • Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment

Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment

Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment

SEATTLE, April 20, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be effective in reducing survival of myelofibrosis...

View More : http://www.prnewswire.com/news-releases/preclinical-data-presented-at-aacr-indicate-pacritinibs-potential-to-eradicate-t...

Releted News by prnewswire

Henrik Edlund tillträder som VD för Futurice Sweden

SAP SE: Cloud Revenue Up 33% - IFRS EPS Up 38% - Non-IFRS EPS Up 9%